A Multi-Centre 3-Arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-Resistant Prostate Cancer
This study has been completed.
Information provided by:
Boehringer Ingelheim Pharmaceuticals
First received: June 24, 2008
Last updated: February 4, 2009
Last verified: February 2009
The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic, bone and PSA criteria.
Drug: BIBF 1120
Drug: BIBW 2992
Drug: Sequential BIBF 1120 + BIBW 2992
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||A Multi-Centre 3-Arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-Resistant Prostate Cancer
Primary Outcome Measures:
- Progression free rate (defined by a composite endpoint of absence of PSA, bone metastasis and RECIST progression) after 12 weeks of treatment in each of the treatment arms. [ Time Frame: up to 48 weeks ]
Secondary Outcome Measures:
- To establish progression free rate at 24 and 48 weeks (based on the composite criteria) To determine time to PSA progression through 48 weeks (PSAWG criteria) To determine RECIST tumour progression rate at 12, 24, 36 and 48 weeks [ Time Frame: up to 48 weeks ]
| Study Start Date:
| Primary Completion Date:
||December 2008 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Age >18 years.
- Signed informed consent.
- Able to comply with protocol requirements.
- Histologically, cytologically or biochemically documented adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa).
- Progressive Disease (PD) is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression.
- Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in trial one of the following criteria is also required:
- Following the completion of the anti-androgen withdrawal period one PSA higher than the last pre-withdrawal PSA.
- Or Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, he can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir.
- PSA > 5ng/mL.
- Life expectancy of at least 12 weeks.
- ECOG performance status 0-1 (see appendix 11.2).
- Stable analgesia requirements.
- Adequate hepatic function: total bilirubin < 26µmol/L, ALT and/or AST < 1.5x upper limit of normal (ULN).
- Adequate renal function: serum creatinine < 1.5 x ULN.
- INR Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 upper limit of normal.
- Absolute neutrophil count (ANC) > 1.5 x 109l, Platelets > 100 x 109/l.
- Haemoglobin > 9.0 g/dl.
- LVEF > 50 % on MUGA scan or echocardiogram.
- Castrate testosterone level [< 20ng/dl or <0.69nM (nM/L x 28.8 = ng/dl)], which must be maintained during the duration of the trial by orchidectomy or medical castration.
- Patient on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.
- Prior treatment with inhibitors of EGFR, HER 2 and/or VEGF receptors.
- Prior treatment with cytotoxic chemotherapy.
- Known hypersensitivity to the trial drugs or their excipients.
- Systemic corticosteroids 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded.
- Treatment with any investigational drug within 28 days of trial onset.
- History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
- Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
- Major injuries and/or surgery within 4 weeks of trial onset or bone fracture and planned surgical procedures during the trial period.
- Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > NYHA II) (see appendix 11.5).
- History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
- Patient with history or clinical evidence of CNS disease or brain metastases.
- Patients with symptoms of impending or established spinal cord compression.
- Gastrointestinal disorders or abnormalities that would inhibit absorption of the trial drug.
- Patients who require full-dose anticoagulation.
- Radio- or immunotherapy within the past four weeks prior to treatment with the trial drug.
- Patients unable to comply with the protocol.
- Active alcohol or drug abuse.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00706628
|1239.3.4402 Boehringer Ingelheim Investigational Site
|Belfast, United Kingdom |
|1239.3.4406 Boehringer Ingelheim Investigational Site
|Bournemouth, United Kingdom |
|1239.3.4408 Boehringer Ingelheim Investigational Site
|Brighton, United Kingdom |
|1239.3.4409 Boehringer Ingelheim Investigational Site
|Cheltenham, United Kingdom |
|1239.3.4405 Boehringer Ingelheim Investigational Site
|Glasgow, United Kingdom |
|1239.3.4403 Boehringer Ingelheim Investigational Site
|Newcastle Upon Tyne, United Kingdom |
|1239.3.4411 Boehringer Ingelheim Investigational Site
|Southampton, United Kingdom |
|1239.3.4401 Boehringer Ingelheim Investigational Site
|Sutton, United Kingdom |
|1239.3.4410 Boehringer Ingelheim Investigational Site
|Truro, United Kingdom |
Boehringer Ingelheim Pharmaceuticals
||Boehringer Ingelheim Pharmaceuticals
No publications provided
||Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 24, 2008
||February 4, 2009
||Great Britain: MHRA
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 22, 2013
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male